ArticleCurrent pharmaceutical biotechnology2026
The Effects of 1,8-Cineole Treatment on Benign Prostatic Hyperplasia in Rats.
Article in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stigmasterol as a ptotential phytotherapeutic agent for benign prostatic hyperplasia: modulation of inflammation, oxidative stress, and apoptosis.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBenign prostatic hyperplasia is a non-malignant growth of the prostate gland; it's the most common prostatic growth in aging men. 1,8-cineole is a natural compound that is extracted from the essential oil of several aromatic plants including Eucalyptus spp. Recent studies have demonstrated the anti-inflammatory, antioxidant, and anticancer activities of 1,8-cineole. This study aims to investigate the effects of 1,8-cineole treatment on the development of BPH induced by testosterone in rats.
methodsThirty adult male rats were divided into three groups (n=10): a control group, an untreated BPH group that received subcutaneous injections of testosterone (3 mg/kg), and a BPH+cineole group that received 50 mg/kg of cineole intraperitoneally in addition to testosterone for 21 days. Histological changes, serum testosterone, and dihydrotestosterone (DHT) levels, prostatic tissue content of the inflammatory biomarkers interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), oxidative stress biomarkers superoxide dismutase (SOD) and malondialdehyde (MDA), angiogenesis biomarker vascular endothelial growth factor (VEGF-A), cellular proliferation biomarker proliferating cell nuclear antigen (PCNA), transforming growth factor beta-1 (TGF-β1), and pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes were analyzed.
resultsCineole treatment led to a reduction in the prostate weight-to-body weight ratio, as well as the restoration of histopathological changes caused by testosterone. Cineole treatment reduced the serum levels of testosterone and DHT, and the prostatic tissue levels of IL-1β, TNF-α, VEGF-A, PCNA, and TGF-β1 compared to those in the BPH group. Additionally, cineole treatment enhanced the SOD activity and decreased the MDA levels in the prostate tissue. Finally, the mRNA expression of the Bax was increased, while the expression of the Bcl-2 was decreased by cineole.
conclusionOur results highlight the effectiveness of cineole in preventing BPH development in rats. This preventive effect was attributed to the regulation of inflammatory responses, oxidative stress, cellular proliferation, and apoptosis.
Indexed as
Identifiers
39844398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.